was 2.72% in 2011 and 2.87% in 2012. Between 2013 and 2015, the prevalence increased from 3.87% to 4.60%. The greatest increase in prevalence was observed among those in the youngest age group (11-25 years), a 76% increase from 2011 to 2012 and a 42% increase from 2013 to 2015.
Conclusions. In Massachusetts, the OUD prevalence was 4.6% among people 11 years or older in 2015. Massachusetts has been particularly affected by opioid use disorder (OUD) and overdose, with opioid overdose rates 30% higher than the national average. 1 This is despite the state being in the lowest quartile in terms of opioid prescribing rates 2 and despite there being widespread access to insurance coverage for addiction treatment 3 and to naloxone rescue programs. 4 Also, OUD places people at risk for health problems including HIV, hepatitis C virus (HCV), and bacterial infections. 5 Current OUD prevalence estimates are typically derived from individuals who are engaged in some level of care 6 or who selfreport their status. 7 However, a large proportion of individuals with OUD are not in contact with health care services, 8 and stigmatized outcomes are known to be underreported on surveys 9 ; therefore, OUD prevalence is likely underestimated. 7 Amid dramatic increases in opioid overdose deaths linked to the introduction of illicitly produced fentanyl and potentially other high-potency synthetic opioids, 10 accurate estimates of OUD prevalence are important to understand whether the pool of people at risk for overdose death is also increasing. Thus, the true prevalence can be more accurately estimated in an indirect manner.
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Capture-recapture, a method that has been increasingly used in human populations to estimate problem drug use, 11 civilian casualties of war, 12 and traffic-related injuries, 13 can be applied to indirectly estimate the true OUD prevalence.
Accurate OUD prevalence estimates are needed to adequately address the growing opioid epidemic in Massachusetts and nationally. We performed a capture-recapture analysis to estimate the annual prevalence of OUD in Massachusetts from 2011 to 2015.
METHODS
We conducted a multisample stratified capture-recapture analysis to estimate the annual OUD prevalence in Massachusetts between 2011 and 2015. The capture-recapture method is common in epidemiological studies and was originally developed to estimate the size of closed wildlife populations. 14 As an example scenario, at time x 200 fish are captured, tagged, and released, which is known as the "capture" stage. These 200 fish are the "known" population. At time y, 100 fish are recaptured, 10 of which are found to have been tagged previously. The Lincoln-Peterson method assumes that the fraction of tagged fish in the "recapture" (10/100) is proportional to the fraction of fish initially captured in the total population (200/n). 15 Thus, the total population can be estimated (n = 2000). The estimated 1800 remaining fish represent the "unknown" population. This simple approach is adequate when certain assumptions are met (e.g., capture in the second sample is independent of capture in the first sample and the capture probabilities are homogeneous across all individuals in the population). 16 Log-linear models are used when more than 2 databases are involved and when there may be dependence among databases and heterogeneity in the population, as is the case in this analysis. 16 The International Working Group for Disease Monitoring and Forecasting provides a description of the methodology used in applying multisample capture-recapture techniques in epidemiology.
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Data Source
Chapter 55 of the Massachusetts Acts of 2015 (hereafter Chapter 55) mandated that the Massachusetts Department of Public Health analyze data from several of the state's government agencies in an effort to identify and report on trends among individuals who had suffered a fatal or nonfatal opioid overdose. Linkage across databases at the individual level allowed analysts to gain a deeper understanding of the circumstances that influence fatal and nonfatal opioid overdoses.
We analyzed 2011 to 2015 information from the assembled data set, which included all people 11 years or older with a medical claim in the Massachusetts All-Payer Claims Database (APCD) from January 1, 2011, until December 31, 2015. 18 The APCD is a database that includes reimbursement claims submitted by nearly all health care providers in Massachusetts. The Chapter 55 data set linked claims-level data from the APCD to other state databases that include individuallevel demographic and other information (Table 1) . Each individual was de-identified and assigned a unique identification number by the Massachusetts Department of Public Health that was consistent across all databases. Although we used the same methods to estimate the prevalence for each year, we stratified our overall analysis by calendar period because the 2011 and 2012 analyses drew from 6 databases and the 2013 to 2015 analyses drew from 7 databases.
Inclusion and Exclusion Criteria
We included individuals who were identified as having OUD within any of the databases (2011-2012 or 2013-2015) . We excluded people without a recorded age, sex, or county of residence because these cases would have resulted in an unknown denominator in our stratified prevalence estimates.
Analysis Steps
Identifying individuals with known OUD.
We identified individuals with markers consistent with OUD in any of the selected databases (Table 1 The sum of the cells represented the known population. As such, the example individuals just described may have had different (or no) interactions with the databases in subsequent years. For instance, an individual identified in 2012 in the APCD only may have subsequently been identified in both MATRIS and the death records in 2013. In these cases, they would have been placed in unique cells according to the databases in which they interacted during a given year.
Constructing multivariable statistical models estimating the unknown population. We first used the Akaike information criterion with a sample of strata to determine whether standard Poisson, zero-inflated Poisson, negative binomial, or zero-inflated negative binomial models were the best fit for the data. 19 The models with the lowest Akaike information criterion values in the sample tested were the standard Poisson and negative binomial models, which were very similar to one another. We chose the negative binomial model instead of the standard Poisson model in each stratum to account for overdispersion of the data. In addition, we considered all of the possible interaction terms in each model to capture the impact of the overlap across the databases. This allowed for a more precise estimate of the unknown population with a smaller standard error. To determine which interaction terms to retain in the final models, we used stepwise selection methods based on statistical significance to ensure that each model was hierarchically well formed; higher-level interaction terms were considered only if lower-level terms were included. The final model provided estimates of the unknown population by strata (Tables A-E, available as supplements to the online version of this article at http://www.ajph.org).
Estimating confidence intervals. We derived confidence intervals (CIs) for each age group stratum and the overall population. Because we could not derive theoretical estimators of the confidence intervals for these sums, we used a bootstrap method to obtain confidence intervals for estimates representing sums of the stratum-specific estimates. Bootstrap confidence intervals were constructed under independent and identically distributed assumptions, which were conservative in this case because we did not have identically distributed variables (i.e., each county used a different probability model). 20 We obtained state-level estimates by summing all county-and age-specific estimates and denote this as S n , where n is the total number of strata. Using the model that was selected for each stratum, we randomly generated 10 000 realizations of the unknown populations and summed each of these values to obtain 10 000 state-level estimates, denoted as S n *. In line with the method described by Liu and Singh, we defined the confidence intervals as
where B 1Àa and B a are the 2.5th and 97.5th quantiles of the empirical distribution of p nðS Ã n À S n Þ. 20 We calculated the total OUD population by summing the total known population (those identified in any database during each year) and the estimated unknown population (those estimated with the models).
Conducting sensitivity analyses. We performed a sensitivity analysis in which we removed Registry of Vital Records and Statistics (RVRS) death records from the 2015 analysis to ensure that the increase in opioid-related overdose deaths due to fentanyl was not driving the most proximal year's prevalence estimate. Because data from MATRIS became available in 2013 (and thus this was the seventh database used for the years 2013-2105), we performed another sensitivity analysis in which we excluded MATRIS and the RVRS death record databases from Suspected opioid overdose (Table L, the 2013 data. We excluded MATRIS in 2013 to determine the degree to which estimates may have been affected by MATRIS being unavailable in 2011 and 2012. Incorporating an alternative model development approach. We used an alternative model development approach for our 2015 analysis to ensure the robustness of our primary analysis (see the appendix, available as a supplement to the online version of this article at http://www.ajph.org). We initially determined that at least 4 databases were necessary for an accurate estimation of the known population, as inclusion of fewer data sources led to markedly different population estimates, implying that valuable information would have been lost with a smaller number of sources. We then constructed a series of models that included all possible permutations of 4 databases (35 combinations), 5 databases (21 combinations), 6 databases (7 combinations), and 7 databases (1 combination). Each model was built initially including only 2-way interaction terms and then including all 2-and 3-way terms.
RESULTS
The prevalence of OUD in Massachusetts among people 11 years or older was 2.72% in 2011 and 2.87% in 2012 (Table 2 ). In 2013, once all 7 databases were available, the prevalence was 3.87%, followed by an increase to 4.60% in 2015 ( Table 2) In 2015, the estimated prevalence ranged from 3.17% in Dukes and Nantucket counties to more than 6% in Berkshire County ( Figure  A , available as a supplement to the online version of this article at http://www.ajph. org). The highest prevalence estimates were in counties with substantial rural populations such as Barnstable, Berkshire, Bristol, Hampden, and Worcester (5.03%, 6.06%, 5.81%, 5.34%, and 4.38%, respectively). The 2015 prevalence in the urban county of Suffolk, which encompasses Boston, was 3.36%.
With respect to age, the prevalence was highest among individuals 26 to 44 years old and 45 years old or older (6.87% and 4.66%, respectively, in 2015). Although members of the youngest age group had the lowest absolute prevalence estimates across all years In the 2015 sensitivity analysis that excluded the RVRS death records, OUD prevalence was largely unchanged at 4.47%. There were 119 094 known individuals with OUD (596 less than shown in the primary analysis) and 148 010 estimated "unknown" people with OUD (7370 less than in the primary analysis). In the 2013 sensitivity analysis that excluded RVRS death records and MATRIS, the prevalence was 2.65% (as compared with the preceding figure of 3.87%) . Exclusion of these databases resulted in 5477 fewer known individuals and an estimated 22 295 additional unknown individuals. In our 2015 alternative model development approach, we found that there were positive interactions between databases that contributed the most to the "known" population (i.e., those demonstrating interactions with hospitals or substance use treatment, such as APCD, the Bureau of Substance Abuse Services databases, Case Mix, and the Prescription Drug Monitoring Program database) and negative interactions when other databases were included (i.e., MATRIS or RVRS death records in which individuals may not otherwise interact with the health care system; Figures B and C, available as supplements to the online version of this article at http://www.ajph.org). We also found that the variability of our estimates decreased as more databases were added and that, relative to our primary analysis, models with 2-way interactions resulted in lower estimates and models with 2-and 3-way interactions led to higher estimates ( Figure D , available as a supplement to the online version of this article at http://www.ajph.org).
DISCUSSION
We estimated that the total population prevalence of OUD in Massachusetts reached 4.60% in 2015, nearly 4 times higher than current national prevalence estimates. 6 From 2011 to 2015, opioid-related overdose deaths also surged from 656 to 1793 per year, a 273% increase. 21 Although the surge in overdoses in Massachusetts has primarily been attributed to the introduction of fentanyl into the heroin market, 10 the high prevalence of OUD is probably also contributing to the stark increase in overdose deaths. Together, our findings suggest a complex epidemiology of overdose deaths in which the alarming increase in mortality likely reflects both more people using opioids and an increased overdose mortality risk among those with OUD.
Our approach, which involved capturerecapture analyses of several individually linked databases, represents a substantial improvement over other approaches, which are typically based on solely the prevalence of individuals who are known in a registry or database or on surveys in which reporting bias is frequent. Several reasons may explain why people with OUD are "unknown" and, thus, may be underreported. First, OUD remains a highly stigmatized disease, and individuals may be reticent to engage with the health care system. 22 Second, treatment barriers exist for this population, limiting care for OUD. 8 Individuals with OUD are less likely than members of the general population to have medical insurance even in Massachusetts, where a large proportion of residents are insured. 23 Finally, fear of legal consequences of opioid use has contributed to disengagement with medical care. 24 Our results demonstrate that the scope of the opioid epidemic in Massachusetts may be larger than previously estimated. In this study, the prevalence estimate derived solely from the known OUD population was nearly half (e.g., 1.11% in 2011 and 2.00% in 2015) the estimate obtained via capture-recapture. Still, the numbers for the known OUD population alone are higher than national prevalence estimates. 6 We found, unsurprisingly, that OUD prevalence varied by county and age group. Counties with higher prevalence estimates in 2015 also had some of the highest reported annual opioid-related death rates in 2013 to 2014. 25 In general, the prevalence was higher in rural counties than in urban counties. The prevalence of OUD did not consistently increase or decrease with the size of the county population ( Figure A) . This result is consistent with findings from other states and has challenging policy implications with respect to optimal allocation of services. 26 Another striking finding was that the largest prevalence increases, from 2011 to 2012 and from 2013 to 2015, were observed in the youngest age group. Other researchers have noted increases in OUD and overdose among young adults. 27 Indeed, estimates of opioid overdose deaths continued to increase through 2016. 25 Finally, we estimated that fewer than 50% of people with OUD were "known" to the health care system, a critical first step in the OUD treatment continuum. Three plausible explanations account for this phenomenon. First, we included in our analysis only variables considered as representing "certain OUD." In doing so, we excluded individuals who may have OUD but did not have an explicit indicator of consequential opioid use in any of the databases. For instance, an HCV-infected individual with endocarditis probably has OUD, but if the individual was not captured in any database with the specified OUD variables, he or she was not included as "known." Such an individual may, however, have been estimated as "unknown" with capture-recapture. This process would therefore result in a proportion of "known" individuals lower than that actually existing because they would be counted as "unknown."
Second, because barriers such as stigma and cost prevent people with OUD from accessing and engaging with the health care system, this lack of contact would keep them from being captured. However, these are precisely the people who are estimated via capture-recapture. Finally, it remains possible that more individuals with OUD are accessing health care but that care providers are not documenting this diagnosis. 28 Our results demonstrate that there is work to be done to identify the large number of people with OUD who remain "unknown" to the treatment systems that contributed to our data set.
Limitations and Strengths
Some limitations of our study merit attention. The methodology we used is an imperfect tool for estimation and is bound by several underlying assumptions: (1) the capture probabilities for different databases are independent, (2) the probability of capture by a given data set is assumed to be the same for each individual in the population, (3) the population does not change from capture to capture, and (4) matches are accurately identified. We addressed these assumptions in the following ways.
Initially, we used log-linear modeling with significant interaction terms to account for dependence and heterogeneity. We stratified our data according to available covariates in an attempt to adjust for dependence and heterogeneity. It remains possible that we did not completely account for factors associated with fentanyl use, which could have introduced dependence between databases. There could be, for example, unaccounted geographic heterogeneity or differences in penetration of fentanyl among various age groups, resulting in dependence. Next, we limited each analysis to a 1-year period, and as such we assumed a certain level of population stability.
Another potential limitation is the issue of case identification. There were missing data in Chapter 55, which could have affected our results. For example, because MATRIS was unavailable until 2013, we were not able to compare estimates across all 5 years. Our sensitivity analysis demonstrated that including MATRIS increased estimated OUD prevalence. MATRIS is a novel data set that captures many individuals not captured by any other data source. When many more individuals are captured by only one data source than would be expected by chance alone, this implies that there are many people who remain unknown. This is a strength of the capture-recapture approach.
Importantly, including MATRIS did not structurally bias our analysis toward a higher prevalence. 11 If OUD prevalence were better characterized, adding MATRIS to the analysis would simply have confirmed the estimates obtained without that database and, perhaps, narrowed the confidence intervals. We cannot be certain whether the estimates obtained with MATRIS were overestimates or whether those obtained in its absence were underestimates. However, the MATRIS prevalence estimates behave as would be expected when an additional novel data source is included; also, they are similar to trends in known OUD during the same time period and align well with Massachusetts prevalence estimates made independently and according to a different approach. 29 This limitation does, however, make it difficult to compare trends between the different periods. To address this issue, we divided our analysis into years including (2011-2012) and not including (2013-2015) MATRIS. Finally, our conservative definition of OUD may have resulted in people with known OUD being missed.
Public Health Implications
We estimated that the OUD prevalence in Massachusetts among individuals aged 11 years or older was 4.60% in 2015. Our results contribute to the growing body of evidence that the US opioid crisis is expanding and is worse among young people and in certain geographic locations such as the Northeast. 30 Along with complementary surveillance approaches, 31 the capture-recapture method may be useful in accurately assessing OUD prevalence in other states.
In Massachusetts, along with the wide distribution of illicitly manufactured fentanyl, the growing OUD prevalence is likely contributing to the surge in opioid-related deaths. Similarly, there have been notable increases in acute HCV infection 32 and serious bacterial infections 33, 34 attributable to injection opioid use. These infections will likely continue to rise as OUD prevalence increases and as individuals transition to injection opioid use. 35 Additional resources for prevention and treatment of OUD, as well as opioid-related overdoses and infectious complications, will be key in effectively combating this disease.
